Celcuity (CELC) Q4 2025 earnings review
NDA Accepted with Priority Review, but Launch Costs are Accelerating
Celcuity has officially crossed the threshold from clinical-stage R&D to active commercial preparation. The FDA accepted the New Drug Application (NDA) for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer, granting Priority Review with a PDUFA date of July 17, 2026. While the clinical narrative remains exceptionally strong—highlighted by staggering 16.6-month median PFS in US/Western subgroups—operating expenses are accelerating rapidly. G&A expenses surged 286% YoY as the company builds its commercial footprint. With $441.5M in the bank, the company is fully funded through a prospective Q3 2026 launch, though investors will have to wait until Q2 2026 for the delayed PIK3CA mutant cohort data.
🐂 Bull Case
The FDA's decision to grant Priority Review sets a firm July 17, 2026 PDUFA date, potentially allowing commercial launch in Q3 2026. This fast-tracks the revenue timeline for the PIK3CA wild-type indication.
Updated VIKTORIA-1 data showed patients in the US, Canada, Western Europe, and APAC achieved a median PFS of 16.6 months on the gedatolisib triplet, vastly outperforming the 1.9 months for the fulvestrant control.
🐻 Bear Case
Topline data for the PIK3CA mutant cohort was originally guided for late 2025, but has officially slipped to Q2 2026, delaying the potential expansion of the addressable market.
Transitioning to a commercial-stage organization is expensive. Q4 net loss hit $51.0M, and execution risk is paramount as Celcuity attempts its first independent U.S. commercial drug launch.
⚖️ Verdict: 🟢
Bullish. The core thesis is intact: gedatolisib works exceptionally well. The FDA's Priority Review validates the unmet need, and the $441.5M war chest ensures Celcuity can aggressively fund its proprietary launch without immediate dilution, despite the mutant cohort data delay.
Key Themes
Exceptional Western Subgroup Efficacy
Celcuity provided updated VIKTORIA-1 PIK3CA wild-type data at the San Antonio Breast Cancer Symposium, revealing a profound geographic divergence. For patients enrolled in the U.S., Canada, Western Europe, and Asia Pacific, the median progression-free survival (PFS) was 16.6 months with the triplet regimen vs. 1.9 months for fulvestrant (HR=0.14). This is significantly higher than the 9.3 months global median PFS reported earlier in the year, providing a massive commercial selling point for the upcoming U.S. launch.
Commercial Build-Out Driving OpEx Acceleration
Operating expenses are accelerating aggressively as the company scales its commercial infrastructure. G&A expenses skyrocketed 286% YoY to $11.6M in Q4 2025 (up from $3.0M in Q4 2024). Within R&D, $5.3M of the $8.6M increase in personnel/consulting was directly tied to commercial headcount additions and launch-related activities. Investors should expect this elevated burn rate to be the new baseline through 2026.
Quality of Life (PRO) Data Supports Adoption
Beyond raw survival metrics, Celcuity reported compelling Patient Reported Outcomes (PRO). The median time to definitive deterioration of well-being (EQ-5D-5L score) was delayed to 23.7 months for the gedatolisib triplet versus just 4.0 months for the control arm. In a palliative metastatic setting, preserving quality of life is a critical driver for physician prescribing behavior.
PIK3CA Mutant Cohort Data Slipped to Q2 2026
The timeline for the Phase 3 VIKTORIA-1 PIK3CA mutant cohort data is decelerating. Early in 2025, management guided for Q4 2025. In Q3, it was amended to 'Late Q1 or during Q2 2026'. The current release firmly places it in Q2 2026. While the wild-type population is the primary focus of the current NDA, the mutant cohort is critical for maximizing total addressable market and attracting potential ex-U.S. partners.
High Rates of Grade 3+ Neutropenia
Stable but notable safety profile: 62.3% of patients on the gedatolisib triplet experienced Grade 3+ neutropenia, compared to 0.8% on control. While the study discontinuation rate due to treatment-related adverse events remained remarkably low at 2.3%, managing this high rate of severe neutropenia in community oncology settings will be a hurdle the future sales force must actively educate physicians on.
Other KPIs
Accelerating. The net loss widened from $36.7M in Q4 2024. A substantial portion of the increase is non-cash, with total stock-based compensation reaching $9.45M for the quarter (up from $2.3M YoY). Adjusted non-GAAP net loss, which excludes these non-cash items, was $38.4M.
Accelerating burn. Up from $27.8M in Q4 2024, reflecting the cash toll of clinical trials and the front-loading of commercial headcount ahead of the potential Q3 2026 launch. Full-year operating cash burn reached $153.3M.
Stable. The company exited FY2025 in a highly secure financial position, largely thanks to the $287M convertible note and equity raise executed in July 2025. This balance sheet strength de-risks the proprietary U.S. launch strategy.
Guidance
This is a firm date granted alongside Priority Review status for the gedatolisib NDA in HR+/HER2-/PIK3CA WT advanced breast cancer. This target sets the clock for the commercial sales force rollout.
Stable. The company reaffirmed that its $441.5M in cash and short-term investments will fund operations through 2027, comfortably covering the commercial launch phase and ongoing Phase 3 trials without the immediate need for dilutive equity offerings.
Decelerating. Pushed from initial late-2025 estimates. This data will be critical for a potential supplemental NDA and for finalizing ex-U.S. commercialization partnerships.
Key Questions
Subgroup Efficacy Divergence
The median PFS in the US/Canada/WE/APAC subgroup for the triplet was 16.6 months, compared to the 9.3 months reported for the broader global trial population earlier this year. What specific baseline patient characteristics or prior treatment patterns drove this massive 7-month geographic divergence?
Mutant Cohort Timeline
The PIK3CA mutant cohort data readout has moved from late 2025, to Q1/Q2 2026, and now firmly to Q2 2026. Is this delay primarily driven by a slower-than-expected event rate, or were there logistical delays in data cleaning?
Commercial Force Sizing
With the PDUFA date set for July 17, 2026, how many specialized oncology sales representatives do you plan to have fully hired and trained by Q3, and what is the expected ongoing quarterly run-rate for SG&A post-launch?
Managing Grade 3+ Neutropenia
Given the 62.3% rate of Grade 3+ neutropenia in the triplet arm, what specific resources or programs are being developed by your commercial and medical affairs teams to ensure community oncologists are comfortable managing this profile outside of a clinical trial setting?